Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Regeneron Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Accounts payable 380,100  347,800  418,100  335,600  244,000  239,600  218,200  172,361  171,906  207,611  178,183  —  —  —  —  —  —  —  —  —  —  — 
Accrued expenses and other current liabilities 1,257,000  1,143,200  1,086,800  821,100  876,700  741,100  772,100  781,924  670,709  666,216  637,162  818,760  716,761  1,062,653  880,274  718,502  763,338  746,784  657,675  579,934  531,796  464,947 
Debt 1,500,000  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Finance lease liabilities, current portion —  —  —  —  —  —  —  —  —  —  —  —  —  7,200  129,557  —  —  —  —  —  —  — 
Deferred revenue, Sanofi 380,200  398,000  395,500  427,100  424,300  334,100  246,700  246,812  308,179  231,447  177,746  187,036  184,452  112,161  115,267  105,041  104,141  99,314  101,573  100,908  18,026  19,342 
Deferred revenue, other 81,300  81,200  196,200  181,600  168,100  196,600  205,800  216,133  180,396  160,466  142,392  132,832  127,804  126,257  116,397  137,642  84,084  73,626  51,914  54,148  51,720  51,845 
Other liabilities, Sanofi 103,800  85,000  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Current liabilities 3,702,400  2,055,200  2,096,600  1,765,400  1,713,100  1,511,400  1,442,800  1,417,230  1,331,190  1,265,740  1,135,483  1,138,628  1,029,017  1,308,271  1,241,495  961,185  951,563  919,724  811,162  734,990  601,542  536,134 
Finance lease liabilities, excluding current portion 715,900  715,200  713,900  712,700  711,300  709,900  708,500  707,203  705,903  704,645  703,453  702,317  701,173  700,407  351,569  382,228  361,523  362,230  362,919  364,144  357,687  328,394 
Deferred revenue, Sanofi 37,800  16,200  509,700  551,900  544,200  633,700  279,300  421,196  339,040  406,778  379,936  408,786  443,904  520,191  503,474  529,791  549,342  565,773  582,664  599,339  46,095  48,656 
Deferred revenue, other 67,000  65,900  109,300  131,900  181,200  178,800  184,900  197,651  199,401  257,967  249,263  274,666  295,621  316,227  327,298  327,868  146,449  170,658  82,015  78,942  76,748  114,318 
Other liabilities, Sanofi 390,300  450,500  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Convertible senior notes —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  30,723  30,360  144,082 
Other noncurrent liabilities 457,900  321,500  286,000  273,000  267,900  376,300  361,700  194,033  190,020  169,922  152,073  125,225  115,920  106,248  100,385  135,700  119,523  120,993  115,535  77,910  76,080  55,559 
Noncurrent liabilities 1,668,900  1,569,300  1,618,900  1,669,500  1,704,600  1,898,700  1,534,400  1,520,083  1,434,364  1,539,312  1,484,725  1,510,994  1,556,618  1,643,073  1,282,726  1,375,587  1,176,837  1,219,654  1,143,133  1,151,058  586,970  691,009 
Total liabilities 5,371,300  3,624,500  3,715,500  3,434,900  3,417,700  3,410,100  2,977,200  2,937,313  2,765,554  2,805,052  2,620,208  2,649,622  2,585,635  2,951,344  2,524,221  2,336,772  2,128,400  2,139,378  1,954,295  1,886,048  1,188,512  1,227,143 
Preferred Stock, $.01 par value; issued and outstanding - none —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Class A Stock, convertible, $.001 par value —  —  —  —  —  —  —  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2 
Common Stock, $.001 par value 100  100  100  100  100  100  100  110  110  110  110  109  109  108  108  107  107  107  106  106  105  103 
Additional paid-in capital 6,263,000  5,211,400  4,428,600  4,388,400  4,263,600  4,160,900  3,911,600  3,841,174  3,712,599  3,611,599  3,512,833  3,570,673  3,449,622  3,190,882  3,029,993  3,314,982  3,156,942  3,049,651  3,099,526  2,880,109  3,118,969  2,812,573 
Retained earnings 8,901,700  8,004,400  7,379,800  6,587,800  5,918,200  5,725,100  5,254,300  4,433,904  3,839,179  3,287,767  2,946,733  2,773,214  2,384,897  1,997,153  1,748,222  1,495,107  1,230,303  1,018,436  852,700  697,706  487,308  292,665 
Accumulated other comprehensive income (loss) 35,500  (9,100) 21,100  16,500  15,800  2,800  (12,300) (10,519) (11,612) (15,594) 640  23,835  2,348  (5,884) (12,840) (2,899) 5,204  4,364  8,572  7,721  19,153  47,904 
Treasury Stock, at cost (6,142,900) (1,073,800) (739,900) (488,400) (441,800) (444,200) (396,400) (396,371) (353,852) (316,240) (316,240) (316,240) (316,240) (316,240) (316,240) (316,052) (316,052) (307,478) (306,069) (288,777) (287,079) (181,817)
Stockholders’ equity 9,057,400  12,133,000  11,089,700  10,504,400  9,755,900  9,444,700  8,757,300  7,868,300  7,186,426  6,567,644  6,144,078  6,051,593  5,520,738  4,866,021  4,449,245  4,491,247  4,076,506  3,765,082  3,654,837  3,296,867  3,338,458  2,971,430 
Total liabilities and stockholders’ equity 14,428,700  15,757,500  14,805,200  13,939,300  13,173,600  12,854,800  11,734,500  10,805,613  9,951,980  9,372,696  8,764,286  8,701,215  8,106,373  7,817,365  6,973,466  6,828,019  6,204,906  5,904,460  5,609,132  5,182,915  4,526,970  4,198,573 

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc.’s current liabilities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s noncurrent liabilities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc.’s total liabilities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc.’s stockholders’ equity increased from Q4 2019 to Q1 2020 but then decreased significantly from Q1 2020 to Q2 2020.